Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma
NCT03585725Phase 1Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2018
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ribavirin in follicular lymphoma (FL) and mantle cell lymphoma (MCL), sponsored by Weill Cornell Medicine. Primary endpoint: Number of participants who receive treatment for at least 3 months and have peripheral blood samples collected. Started Sep 2018; status: terminated.
02
Drugs
ribavirin
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03585725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03585725.